FCCDC SBIR Phase 2: Combinations of Oral Antibiotics to Treat Syphilis. (75N93025C00009)
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $1,500,000 to $3,000,000
- Set-aside
- Total Small Business
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health is forecasting a new requirement, set aside for total small business, for the FCCDC SBIR Phase 2 effort on combinations of oral antibiotics to treat syphilis (75N93025C00009), with an estimated solicitation release date of 2026-09-01 and an estimated award date of 2026-10-01. The effort continues product development of completed early-stage research on an oral therapeutic for syphilis other than benzathine penicillin G (BPG), the current standard of care, which is not available orally and faces frequent shortages in the US and globally. The source cites rising acquired and congenital syphilis rates and recent advances in culturing T. pallidum as reasons alternatives to BPG are now more feasible to identify.
The estimated award value range is $1.5 million to $3 million under NAICS 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). The Contracting Officer is Callie Prassinos of NIH (callie.prassinos@nih.gov, +12406695155), and Jonathan Glock of the National Institutes of Health (jglock@niaid.nih.gov) is also listed as a point of contact.
Forecast text
An application to continue the product development of this successfully completed early-stage research for a therapeutic for treatment of syphilis infection other than benzathine penicillin (BPG). BPG, the current standard of care treatment for syphilis infections, is not available orally and shortages of BPG are common in the US and globally. Alternative therapies to BPG are urgently needed that address this and other barriers to this treatment, as acquired and congenital syphilis rates are increasing rapidly. Recent advances in the ability to culture T. pallidum mean that identification of alternatives to BPG for the treatment of syphilis is now more feasible than has been possible in the past.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast